Follows people with coronary artery disease treated with the SUPRAFLEX CRUZ device
Follows adults with coronary artery disease who received the SUPRAFLEX CRUZ heart device.
Plain-language title generated from the registry record
Registry title: SUPRAFLEX CRUZ PMCF Study ( rEpic05 )
Key facts
- Where
- A Coruña, Barakaldo, Barcelona, Cáceres, Castelló, Ciudad Real, Elche, Girona, Granada, León, Lleida, Madrid, Murcia, Sabadell, Salamanca, Santiago de Compostela, Seville, Toledo, Valencia, and Zaragoza, SpainSee the 21 sites
Where in Spain
- Hospital Universitario A CoruñaA Coruña, SpainTaking people
- Hospital Universitario de CrucesBarakaldo, SpainTaking people
- Hospital de la Santa Creu i Sant PauBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital Universitario San Pedro de AlcántaraCáceres, SpainTaking people
- Hospital General Universitario de CastellónCastelló, SpainTaking people
- Hospital General Universitario de Ciudad RealCiudad Real, SpainTaking people
- Hospital General Universitario de ElcheElche, SpainTaking people
- Hospital Universitari Dr. Josep TruetaGirona, SpainTaking people
- Hospital Universitario Clínico San CecilioGranada, SpainTaking people
- Hospital Universitario De LeonLeón, SpainTaking people
- Hospital Universitari Arnau de VilanovaLleida, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- Hospital Clínico Universitario Virgen de la ArrixacaMurcia, SpainTaking people
- Hospital Parc TauliSabadell, SpainTaking people
- Hospital Clinico Universitario de SalamancaSalamanca, SpainTaking people
- Hospital Clínico Universitario de Santiago de CompostelaSantiago de Compostela, SpainTaking people
- Hospital Universitario Virgen del RocioSeville, SpainTaking people
- Hospital Universitario de ToledoToledo, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
- Hospital Universitario Lozano BlesaZaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación EPIC
- Trial code
- NCT05617599
- Record updated
- 16 December 2025
- Original description
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Medical Device Regulations (MDR) with multivessel coronary disease requirements in all the CONSECUTIVE patients treated with (SUPRAFLEX CRUZ).Read full original descriptionShow less
SUPRAFLEX CRUZPost-Market Clinical Follow-up Study
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Medical Device Regulations (MDR) with multivessel coronary disease requirements in all the CONSECUTIVE patients treated with (SUPRAFLEX CRUZ).
Inclusion: ≥ 18 years old and; Patients treated with SUPRAFLEX CRUZ according to routine hospital practice and following instructions for use; Patients with multivessel coronary artery disease (understood as that which affects more than one territory of the major epicardial coronary arteries - anterior descending, circumflex, right coronary artery) who is treated with more than 1 stent under study in lesions located in more than 1 of the aforementioned arteries; Substudy: Patients with Ejection Fraction <45% by Echocardiography; Informed consent signed.
Exclusion: Not meet inclusion criteria; Contraindication for antiplatelet treatment; Patient life expectancy less than 12 months.